Updated Warnings for GLP-1 Agonists

The Therapeutic Goods Administration (TGA) has updated the product warnings for GLP-1 and dual GIP/GLP-1 receptor agonists due to a potential risk of suicidal thoughts. Glucagon-like peptide‑1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretins that play important roles in glucose metabolism and energy homeostasis. Medications acting as agonists at GIP and GLP-1 receptors are used in the treatment of type 2 diabetes and weight management.

These medications include:

• Semaglutide;
• Liraglutide;
• Dulaglutide; and
• Tirzepatide.

A potential signal for self-harm and suicidality prompted investigations by the TGA and international regulatory agencies. As of September 2025, the TGA had received 85 such reports, including two reports of completed suicide. While there is insufficient evidence to support a causal link, the TGA notes the complex interaction between mental illness and the disorders for which these medicines are prescribed.

Use of GLP-1 agonists has increased significantly in recent years, particularly for weight loss. The TGA advises healthcare professionals to evaluate the benefits and risks of starting or continuing these medicines in patients with suicidal ideation or a history of suicide attempts. Patients should be monitored for any new or worsening mental health symptoms and encouraged to promptly report any concerning symptoms to their healthcare professional.